EL7.AI
StocksMediumUpdated•Originally published 27 August 2026•Updated 27 August 2026•
1 min read

FDA Approves LISRAYA for Treatment of Dermatomyositis in Adults

Key Facts

1The U.S. FDA approved LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis.
2The new treatment is a once-daily pill and is now available in the United States.

In a move reflecting significant regulatory progress in the biotech sector, the U.S. FDA has approved LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis. Developed by Roivant and Priovant Therapeutics, the new treatment is a once-daily pill and is now officially available in the United States, marking a major milestone for the companies involved as of August 27, 2026.

The approval is supported by clinical data evaluating the efficacy of brepocitinib, a dual TYK2/JAK1 inhibitor, in managing this rare inflammatory condition. According to clinical reports, 62% of patients receiving LISRAYA were able to taper to minimal corticosteroid use by the end of the study period, compared to 38% in the placebo group, highlighting the drug's clinical utility in reducing steroid dependency.

This regulatory milestone is a primary value driver for Roivant, providing a clear path to commercial revenue. While specific instrument price levels are unavailable as of the close on August 27, 2026, the approval is qualitatively bullish for the firm's specialized drug pipeline and its long-term commercial outlook in the autoimmune therapeutic space.

Latest Updates · 1

  1. Notable·

    Update: This approval is strategically significant as LISRAYA becomes the first oral medication officially approved for dermatomyositis. This distinction is expected to strengthen Roivant's competitive position by providing a more convenient administration route compared to previously available non-oral therapies.